# The concentration of Leukemia inhibitory factor in uterine flushing fluid in females with unexplained infertility

Thesis submitted for partial fulfillment
of Master degree in Obstetrics and Gynecology

*Presented by*
**Shimaa Essam Mohamed**
M.B, B.Ch Ain Shams University (2003)

*Under supervision of*
Prof. **Hassan Awwad Bayoumy**
Professor of Obstetrics and Gynecology
Faculty of Medicine
Ain Shams University

Dr. **Amgad Al-Said Abou-Gamrah**
Assistant professor of Obstetrics and Gynecology
Faculty of Medicine
Ain Shams University

Dr**. Mohamed Mahmoud Ahmed Farghali**
Lecturer of Obstetrics and Gynecology
Faculty of Medicine
Ain Shams University

Faculty of Medicine
Ain Shams University
2009

# تركيز العامل المثبط للوكيميا فى سائل غسيل التجويف البطانى للرحم فى السيدات ذوات العقم الغير مفسر

رسالة مقدمة من


الطبيبة/ **شيماء عصام محمد عبد المنعم**

بكالوريوس الطب و الجراحة (2003)
كلية الطب- جامعة عين شمس
توطئة للحصول على درجة الماجستير في امراض النساء والتوليد

تحت اشراف

**أ.د/ حسن عواد بيومى**

استاذ امراض النساء والتوليد
كلية الطب - جامعة عين شمس

د/ **أمجد السعيد أبوجمرة**
استاذ مساعد امراض النساء والتوليد
كلية الطب - جامعة عين شمس

د/ **محمد محمود أحمد فرغلى**

مدرس امراض النساء والتوليد
كلية الطب - جامعة عين شمس

كلية الطب - جامعة عين شمس


**2009**

# Acknowledgement

*I wish to express my deep appreciation and sincere gratitude to* ***Prof. Dr. Hassan Awwad Bayoumy,*** *Professor of Obstetrics and Gynecology, Ain Shams University, for his close supervision, valuable instructions, continuous help, patience and guidance. He has generously devoted much of his time and effort for planning and supervision of this study. It was a great honor to me to work under his supervision.*

*I would like to express my sincere appreciation to* ***Dr. Amgad Al-Said Abou-Gamrah,*** *Assisted Professor of obstetrics and Gynecology, Ain Shams University, for his encouragement, continuous support and revision of all parts of the work. His generous participation and kind cooperation in this work is greatly appreciated*

*My deepest gratitude to* ***Dr. Mohamed Mahmoud Ahmed Farghali ,*** *Lecturer of obstetrics and Gynecology, Ain Shams University, for dedicating so much of his precious time and effort, and for his honest and constant guidance to complete this work, words of thanks are so little for his great help in preparation of this work.*

*I'm also deeply indebted to the great help offered by* ***Dr. Ahmed El Hoseney,*** *Lecturer of obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, to whom I owe many valuable remarks and a lot of precious time and effort,*

*his guidance and kind assistance supported in completing this work.*

*Also, I am in debt for the* ***Infection Control Unit in Faculty of Medicine, Ain Shams University*** *for their help in completing the practical part of this work.*

*It was a real pleasure and honor to work under supervision of* ***My Professors*** *and co-operate with my colleagues to produce this work.*

*Finally, I wish to thank all members of* ***My Family, My Mother*** *and my* ***husband,*** *for their continuous help, encouragement and support.*

# ***Contents***


| Subjects | Page |
|---|---|
| * Introduction | 1 |
| * Aim of the work | 6 |
| * Review of Literature | |
| • Unexplained infertility | 7 |
| - Definitions and Incidence | 7 |
| - Risk factors of unexplained infertility | 8 |
| - Diagnosis of unexplained infertility | 11 |
| - Basic evaluation of infertile couple | 12 |
| - Possible etiologies of unexplained infertility | 25 |
| - Management of unexplained infertility | 41 |
| • Uterine receptivity and implantation | 43 |
| - Preparation for implantation | 47 |
| - Stages of implantation | 49 |
| - Biochemical markers of endometrial receptivity | 55 |
| - Changes of the immune system during WOI | 66 |
| - Methods for assessment of endometrial receptivity | 69 |
| • Leukemia inhibitory factor | 72 |
| - Structure of LIF | 75 |
| - Mode of action | 76 |
| - LIF in the human uterus | 82 |
| - LIF localization | 83 |
| - Regulation of LIF expression in the human | 84 |
| - LIF and implantation | 89 |

- LIF and decidualization ---------- 100
- Other sites for LIF expression ---------- 104
- Endometrial LIF and infertility ---------- 107
- Clinical applications of LIF ---------- 109

* Patients and Methods ---------- 112
* Results ---------- 126
* Discussion ---------- 140
* Summary ---------- 154
* Conclusion ---------- 159
*Recommendations ---------- 160
* References ---------- 161
* Arabic Summary.

# ***List of Abbreviations***

| | |
|---|---|
| AMH | Anti-müllerian hormone |
| aPL | antiphospholipid antibodies |
| ART | Assisted reproductive technology |
| ASRM | American Society for ReproductiveMedicine |
| AUC | Area under the curve |
| BBT | Basal body temperature |
| BMI | Body Mass Index |
| BMP-2 | Bone morphogenetic factor-2 |
| cAMP | Cyclic adenosine monophosphate |
| CAMs | Cell adhesion molecules |
| CATs | Chlamydia Antibody Titres |
| CC | Clomiphence citrate |
| COH | Controlled ovarian hyperstimulation |
| COX | Cyclo-oxygenase |
| CSF-I | Colony-stimulating factor-I |
| DAPCs | Human decidual antigen presenting cells |
| E2 | Estradiol |
| ECM | Extracellular matrix |
| EGF | Epidermal growth factor |
| EGFR | Epidermal growth factor receptor |
| ELISA | Enzyme Linked Immunosorbant Assay |
| EPF | Early pregnancy factor |
| ER | Estrogen receptor |
| ERK | Extracellular signal-regulated kinase |
| ET | Embryo transfer |
| ETBF | Endometrial tissue blood flow |
| FSH | Follicle stimulated hormone |
| GIFT | Gamete intrafallopian transfer |
| GM-CSF | Granulocyte macrophage colonystimulatingfactor |

| | |
|---|---|
| GnRH | Gonadotropin Releasing Hormone |
| gp-130 | Glycoprotein-130 |
| HB-EGF | Heparin binding- Epidermal growth factor |
| HCC | Human choriocarcinoma |
| hCG | Human chorionic gonadotropin |
| HLA | Human leukocyte antigens |
| HS | Highly significant |
| HSG | Hysterosalpingography |
| ICM | Inner cell mass |
| ICSI | Intra-cytoblasmic sperm injection |
| IFN | Interferon |
| IFN-γ | Interferon-γ |
| IGF | Insulin-like growth factor |
| IGFBP-1 | Insulin-like growth factor binding protein-1 |
| IL1 | Interleukin-1 |
| IL-10 | Interleukin-10 |
| IL-2 | Interleukin-2 |
| IL-5 | Interleukin-5 |
| IL-6 | Interleukin-6 |
| IRG1 | Immune response gene 1 |
| IUI | Intrauterine insemination |
| IVF | In-vitro fertilization |
| IVF/ET | In-vitro fertilization/Embryo transfer |
| JAKs | Janus kinases |
| Kb | Kilobase |
| kDa | KiloDaltons |
| KO | Knockout |
| LE | Luminal epithelium |
| LH | Lutenizing hormone |
| LIF | leukemia inhibitory factor |
| LIF-R | Leukemia inhibitory factor receptor |
| LIF-Rb | LIF receptor-b |

| | |
|---|---|
| LPD | luteal phase defect |
| LUF | Luteinized unruptured follicle syndrome |
| M | Mole |
| MHC | Myeloid human cell line |
| MIF | Macrophage migration inhibitory factor |
| MIS | Müllerian-inhibiting substance |
| MMPs | Matrix metalloproteinases |
| mRNA | Messenger ribonucleic acid |
| MUC | Mucins |
| MW | Molecular weight |
| NDL | Normal distribution line |
| NK cells | Natural Killer cells |
| OPN | Osteopontin |
| PCOS | Polycystic ovary syndrome |
| PDGF | Platelet derived growth factor |
| PGE2 | Prostaglangin E2 |
| PI3K | Phosphatidylinositol- 3-kinase |
| PIAS | Protein inhibitor of activated |
| PID | Pelvic inflammatory disease |
| POF | premature ovarian failure |
| PPARd | Peroxisome proliferators activated receptor d |
| PR | Progesterone receptor |
| PR A | Progesterone type A receptor |
| PR B | Progesterone type B receptor |
| PTEN | Phosphatase and tensin homologue |
| RGD | Arginine-glycine-aspartic acid |
| RIF | Recurrent implantation failure |
| RNA | Ribonucleic acid |
| ROC | Receiving operating characteristic curve |
| STAT | Signal transducer and activator of transcription |
| T reg | T-regulatory |
| TGF | Transforming growth factor |

| | |
|---|---|
| TGF-α | Transforming growth factor alpha |
| TGF-β | Transforming growth factor-β |
| Th | T-helper |
| Th1 | T-helper Type1 |
| Th2 | T-helper Type2 |
| TIMPs | Tissue inhibitors of metalloproteinases |
| TNF-α | Tumor necrosis factor-α |
| TNF-β | Tumor necrosis factor-β |
| TSH | Thyroid stimulating hormone |
| TUN | Trophouteronectin |
| uNK | uterine specific natural killer cells |
| VEGF | Vascular endothelial growth factor |
| WHO | World Health Organization |
| WOI | Window of implantation |
| ZIFT | Zygote intrafallopian transfer |
| κB | Transcription factor nuclear factor |

# ***List of Figures***


| **No.** | **Item** | **Page** |
|---|---|---|
| | **A- Figures in the review of literature:** | |
| 1 | Life birth rates per cycle | 9 |
| 2 | Invasion of the trophoblast and embedding | 54 |
| 3 | Up- and down-regulated factors of the proliferative and secretory phase | 66 |
| 4 | scheme of implantation window and the role of LIFin fetomaternal crosstalk | 77 |
| 5 | JAK-STAT-Signal transduction pathway. | 81 |
| 6 | Diagram showing some of the interactions of LIF in the uterus | 96 |
| 7 | Role of leukaemia inhibitory factor in embryonal-endometrial interaction | 99 |
| | **B- Figures of the results:** | |
| 1 | Parity distribution in group (A) | 129 |
| 2 | Comparison between group A and group B as regard age, BMI | 132 |
| 3 | Comparison between both groups as regards Endometrial thickness and day of sampling | 133 |

| No. | Item | Page |
|---|---|---|
| 4 | Comparison between control and patient groups as regards mean values of LIF | 134 |
| 5 | ROC curve analysis showing the diagnostic performance of LIF for discriminating patients with unexplained infertilityfrom those who are fertile | 136 |

# ***List of Tables***


| **No.** | **Item** | **Page** |
|---|---|---|
| | **A- Tables in the review of literature:** | |
| 1 | Normal semen parameters | 13 |
| | **B- Tables of the results:** | |
| 1 | Descriptive statistics for group A | 128 |
| 2 | LIF concentration in group A | 128 |
| 3 | Parity distribution among the control group | 129 |
| 4 | Descriptive statistics for group B | 130 |
| 5 | Laboratory investigations in group B | 131 |
| 6 | LIF concentration in group B | 131 |
| 7 | Comparison between group A and group B as regard age, BMI | 132 |
| 8 | Comparison between both groups as regard day of sampling, and Endometrial thickness | 133 |
| 9 | Comparison between 2 groups as regards LIF concentration | 134 |

| No. | Item | Page |
|---|---|---|
| 10 | Correlation coefficient between LIF versus different parameters in group B | 135 |
| 11 | Diagnostic Validity test for LIF | 136 |
| 12 | ART distribution among group (B) | 137 |
| 13 | ART success among group (B) | 138 |
| 14 | Comparison between cases with ART failure versus cases with ART success in group (B) | 139 |